*Division of Gynecologic Oncology

†Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA

D.N.: conception, data acquisition, data management, statistical analysis, critical analysis, drafting/final editing. N.K.T., E.M.K., A.F.H., L.C., S.H.K., R.L.G.: critical analysis, drafting/final editing. NL (Nawar Latif) supervision, critical analysis, drafting/final editing.

R.L.G.: medical monitor for CAPRI trial by Astra Zeneca. A.F.H.: GSK research fund, GSK advisory board, honoraria for Axess ovarian cancer lecture. The remaining authors declare no conflicts of interest.

Correspondence: Dimitrios Nasioudis, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 1 West Gates, Philadelphia, PA 19104, USA. E-mail: [email protected].